# An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Study · id `cardio:ct-nct01064414` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01064414](<https://clinicaltrials.gov/study/NCT01064414>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01064414

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

## Technical summary

Registry record NCT01064414. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2013-05-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 272 participants (enrolled count; ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Primary completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Results first posted: 2013-05-27 (ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Brazil; Canada; France; Germany; India; Latvia; Malaysia; Mexico; New Zealand; Poland; Romania; Russia; South Africa; South Korea; Spain (ClinicalTrials.gov record NCT01064414, source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01064414-2013-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
- Condition: Diabetes Mellitus, Type 2
- Condition: Renal Insufficiency
- Intervention (Drug): Canagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

## Provenance

Content hash: 2974a5172b238b16ae4aa032a24a4f34135e20a92cbe63b3857f783afbbeb756
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
